Kaleido Biosciences, Inc.
KLDO · OTC
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Market Cap | $100 | $304 | $129 | $418 |
| - Cash | $38 | $46 | $71 | $76 |
| + Debt | $22 | $21 | $20 | $15 |
| Enterprise Value | $83 | $279 | $78 | $357 |
| Revenue | $1 | $1 | $0 | $0 |
| % Growth | 13.2% | – | – | – |
| Gross Profit | -$1 | -$55 | -$1 | $0 |
| % Margin | -113.6% | -5,640.2% | – | – |
| EBITDA | -$85 | -$77 | -$84 | -$59 |
| % Margin | -7,707.6% | -7,896.9% | – | – |
| Net Income | -$90 | -$82 | -$85 | -$62 |
| % Margin | -8,178.3% | -8,371.3% | – | – |
| EPS Diluted | -2.16 | -2.44 | -3.31 | -2.1 |
| % Growth | 11.5% | 26.3% | -57.6% | – |
| Operating Cash Flow | -$77 | -$62 | -$76 | -$46 |
| Capital Expenditures | -$1 | -$4 | -$4 | -$3 |
| Free Cash Flow | -$78 | -$66 | -$79 | -$49 |